Back to results
US 12,428,379 B2Granted
Acylsulfonamide KAT6A inhibitors
AssigneesOlema Pharmaceuticals, Inc., Aurigene Oncology Limited
InventorsBrian R. Hearn, David C. Myles, Reena Chawla, David Yeghikyan, Chandregowda Venkateshappa, Susanta Samajdar, Kalisankar Bera, Suraj Tatyasaheb Gore, Raymond A. Ng
Life of this patent
Estimating the term…
Abstract
The present disclosure describes acylsulfonamide compounds of Formula (J), and pharmaceutically acceptable salts, compositions, methods, and uses thereof. Such compounds are believed to be therapeutically useful as KAT6A inhibitors particularly in the treatment and/or prevention of diseases and disorders mediated by KAT6A in a subject.
Claims27
A compound of Formula (IIc):
- or a pharmaceutically acceptable salt thereof, wherein:
- each R1 is independently —CH3, —CH2CH3, —C(CH3)3, —OCH3, —OCH(CH3)2, —C(CH3)2OH, —C(CH3)(CH2CH3)OH, —F, —Cl, —Br, —CF3, —OCHF2, —OCF3, —OCH2CF3, cyclopropyl, cyclopropyloxy, cyclobutyloxy, or
- or
- two R1 on adjacent carbons together with the atoms to which they are attached combine to form a cyclopentyl, cyclohexyl, dihydrofuran, tetrahydrofuran, methyltetrahydrofuran, 1,3-dioxole, dihydro-1,3-oxazine, or methyldihydrofuran;
- L is —CH2—;
- R2 is
- R3 is —CH3, —OCH3, —CHF2, —CF3, —OCHF2, —OCF3, or cyclopropyl;
- and
- subscript q is 0, 1, 2, 3, or 4.
6 more elements
Dependencies are inferred from the claim text.